In the middle of the 20th century, Fritz Kahn, a German physician, had immense success with a book series on the 'man machine' (ref. 1 ). Driven by his admiration for both technology and physiology, he drew fascinating illustrations and analogies between the human body and the recently developed industrial machines of the 20th century. Seventy years later, we entered the multiomics era, spurred by a massive advance in technology enabling the systematic, quantitative characterization of the cell's molecular machinery (genome, transcriptome, proteome and metabolome).
. However, the perception of metabolites mainly as downstream products -biomarkers of gene and protein activity -has minimized the awareness of their far-reaching regulatory activity. In fact, the metabolome interacts with and actively modulates all other omics levels ( fig. 1 ). Through this interaction, metabolites also serve as direct modulators of biological processes and phenotypes. This concept, whereby metabolites are active entities in biological processes, has been investigated for decades, with the seminal discovery of lactosedependent regulation of gene expression in bacteria from the lac operon 4 ; the finding that glucose, fatty acids and other lipids act as regulators of insulin secretion and sensitivity 5 ; and the discovery of the key cellular roles of the nutrient and energy sensor, mTOR kinase 6 . More recently, with the advent and evolution of meta bolomics technologies, the discovery of metabolites that have biological activity has grown rapidly. Some of the recent examples of metabolite-driven phenotype modulation include the boosting of sirtuin activity by NAD + to protect against age-associated alterations 7 , modu lation of neuronal excitability and plasticity by lactate 8 , orchestration of macrophage activation and regulation of immunity by α-ketoglutarate 9 , the role of malonyl-CoA in controlling neurogenesis in adults 10 , the importance of nitrogen metabolite balance in pertussis toxin production 11 and taurine-induced myelin basic protein expression 12 . Additional studies of cancer cell metabolism have unravelled the important and multiple roles of fumarate, 2-hydroxyglutarate and succinate, as well as other compounds, as oncometabolites, which are broadly defined as small-molecule components of normal metabolism whose accumulation causes signalling dysregulation to establish a milieu that initiates carcinogenesis 13 . Thus, metabolites can considerably impact cell physiology in
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Identification of bioactive metabolites using activity metabolomics In this Review, we describe recent developments in the field of metabolomics that aim to expand our understanding of metabolite bioactivity. We first illustrate the general principles of the phenotype modulation by metabolites, including chemical modification of macromolecules by metabolites and macromoleculemetabolite interactions. We then summarize recent conceptual advances and workflows to characterize the bioactive metabolome in a variety of biological systems. We provide an overview of bioactive metabolite discovery by combining metabolomics with orthogonal experimental and computational biology approaches. We also review recent technological advances that merge metabolomics with cognitive computing and cloud-based computing and further enable the prediction of metabolite bioactivity through data sharing and mining. Altogether, these metabolomics-based workflows for bioactivity discovery and screening, which we collectively term activity metabolomics, have great value as means to identify meta bolites that act as drivers of biological processes and thus to better understand the physiological role of metabolites.
Principles of metabolite activity
Recent mechanistic insights have revealed that active metabolites strongly impact all layers of the omics landscape, from the genome, epigenome and transcriptome to the proteome [14] [15] [16] . Within this framework, the metabolome has two overarching mechanisms to control the functions of DNA, RNA and proteins: chemical modification and metabolite-macromolecule interaction.
Metabolic chemical modification of macromolecules.
Metabolites drive pivotal covalent chemical modifications of DNA and RNA (such as methylation) and of proteins (post-translational modifications). The dynamic signature of these chemical modifications has been shown to considerably affect cellular function.
Post-translational modifications of proteins involve at least dozens of different small molecules that can be covalently bound in an enzymatic reaction to distinct amino acids as in, for instance, lysine acetylation (derived from acetyl-CoA) 17, 18 , cysteine palmitoylation (derived from palmitoyl-CoA 19 ) or acylation (derived from other acyl-CoA species) 20 . It should be noted that acetylation processes also occur nonenzymatically with low overall stoichiometry and unclear functional roles 20, 21 . Other metabolites responsible for post-translational modifications include succinyl-CoA (arginine succinylation), as well as activated sugar molecules (for example, UDP-glucose) for glycosylation and GlcNAcylation 22, 23 ( fig. 2a ). Additional bioactive metabolites have been shown to control anti-inflammatory responses (via alkylation of cysteine residues 24, 25 ) ( fig. 2b) , proteostasis (via polyADP-ribosylation of a proteasome They also influence RNA metabolism by acting on riboswitches and by regulating post-transcriptional modifications. Finally , as cofactors and co-substrates of chromatin-modifying enzymes, metabolites are actively involved in epigenetic regulation. Thus, through metabolomics-based activity screening, it is possible to reveal the roles and mechanisms of metabolites in the regulation of a phenotype. DNMT, DNA methyltransferase; FAHFA , fatty acid ester of hydroxyl fatty acid; GPCR , G protein-coupled receptor ; HAT, histone acetyltransferase; KMT, lysine methyltransferase; PRMT, peptidyl-arginine methyltransferase; RBS, ribosome binding site; SAM, S-adenosylmethionine; TPP, thiamine pyrophosphate.
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www.nature.com/nrm component 26 ) ( fig. 2c ) or enzyme activity (via lysine glutarylation 27 ) ( fig. 2d ). The bioactive metabolites for these processes are itaconate, ATP-ribose and glutaryl-CoA, respectively. Various proteins can also be methylated on their lysine residues by the transfer of a methyl group from S-adenosylmethionine (SAM) (fig. 2e) . Notably, the abundance of many of these metabolite-induced protein modifications is directly dependent on the metabolic state of the cell and as such they represent a powerful means of phenotype modulation 17, 28 . The key modification of DNA is methylation, which involves transfer of a methyl group from SAM to cytosine ( fig. 2e) . By modulating DNA accessibility, DNA methylation represents an important regulator of gene expression 29 . This modification is first established during embryogenesis and continues throughout the life span, and it shows high dynamics between cell types, tiss ues and developmental stages as well as during ageing [29] [30] [31] . SAM and other metabolites, such as glycine, pyruvate, galactose and threonine, also function as cofactors for enzymes involved in post-transcriptional RNA modifications. These RNA modifications act as sensors and transducers of information to control metabolic rate (for example, oxygen consumption) and protein synthesis; however, their effects are still not completely understood 32, 33 . Furthermore, enzymatic histone modifications such as lysine acetylation (derived from acetyl-CoA), lysine and arginine methylation (again, derived from SAM) ( fig. 2e ) and serine phosphorylation (derived from ATP) ( fig. 2a) are key controllers of the epigenomic landscape, directly influencing gene expression, chromosome packaging and DNA repair 34, 35 .
Metabolite-macromolecule interactions. Metabolitemacromolecule non-covalent interactions represent a second mode of cellular activity regulation. Classic examples are the competitive binding of a metabolite to an active site of an enzyme (inhibition) and the alteration of enzyme activity by the binding of a metabolite at a site other than the active centre (allostery). These concepts apply not only to enzymes but also to a variety of regulatory rRNAs (metabolite-controlled riboswitches 36 ), proteins such as signalling receptors and various other classes of molecules.
G protein-coupled receptors (GPCRs) are the beststudied examples of metabolite-activated signalling molecules, and they were among the earliest identified proteins to be developed as drug targets 37 . Among many other receptors, G protein-coupled receptor 91 in mice (GPR91; also known as succinate receptor 1) is activated by succinate to control blood pressure 38 , and GPR40 (also known as free fatty acid receptor 1) is activated by several fatty acids, including palmitic acid hydroxystearic acid (PAHSA), which belongs to a recently discovered class of endogenous lipids 39, 40 ( fig. 3a) . Binding of metabolites to these receptors invokes highly specific signalling responses that lead to specialized cellular activation of signalling networks. This concept also extends to transcription factors and the regulation of gene expression. For example, phytoestrogens derived from diet lead to noncanonical activation of oestrogen receptors and, in this way, modulate cell metabolism fig. 3b ). At the level of transcription and translation, metabolites can act via riboswitches. Metabolites that control riboswitches include lysine, glutamine, cobalamin, thiamine pyrophosphate (TPP) and purines 41 ( fig. 3c ). During this process, metabolites bind to distinct mRNA regions, alter mRNA conformation and ultimately modulate protein translation 41 . The active metabolome also controls the uptake and availability of other essential nutrients. For instance, iron uptake in plants depends on the local presence of reducing agents within the roots 42 . Metabolites can also control highly complex behavioural phenotypes, as is the case for glucose, which is sensed by cells in the brain, regulating hormone secretion and neuronal activity as a means to fine-tune feeding, energy expenditure and its own homeostasis 43 . Many of these examples describe rather well-known biological aspects of the role of bioactive metabolites, yet they also expand the active metabolome to metabolites including amino acids, pyrimidine and purine bases and phospholipids, which were typically considered as building blocks for proteins, nucleic acids and membranes, respectively Oncometabolites, including d-2-hydroxyglutarate, l-2-hydroxyglutarate, succinate and fumarate, were found in cancerous tumours that had mutations in the enzymes corresponding to the generation of these oncometabolites. Gain-of-function mutations were found in isocitrate dehydrogenase (IDH), leading to increased levels of d-2-hydroxyglutarate, and loss-of-function mutations were found in fumarase (FH) and succinate dehydrogenase (SDH), resulting in the accumulation of fumarate and succinate, respectively (reviewed elsewhere 13 ). The accumulation of the oncometabolites in the tumour cells arising from these mutations resulted in a proliferative phenotype.
Importantly, these oncometabolites are not only biomarkers of the diseases, depending on the aberrant activity or the loss of activity of their respective enzymes, but they can also modify and interact with proteins and DNA as described above. Although the full scope of the biological effects of oncometabolites is still an active area of investigation, it has been demonstrated that they modulate protein-protein interaction, alter enzyme activity, lead to changes in protein post-translational modifications and modify the epigenome, all with the effect of propagating cancer.
For many oncometabolites, their bioactivity stems from their inhibition of the α-ketoglutarate-dependent dioxygenases, a class of enzymes that includes prolyl hydroxylases, among which are key negative regulators of hypoxia inducible factor (HIF) 45 . Inhibition of prolyl hydroxylases by oncometabolites results in a phenotype mirroring hypoxia, known as 'pseudohypoxia' , in which the levels of HIF are increased despite normal 
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www.nature.com/nrm oxygen levels. This then leads to the rewiring of cancer cell energy metabolism from oxidative phosphorylation to glycolysis -a phenomenon known as aerobic glycolysis or the Warburg effect. In addition, oncometabolites inhibit α-ketoglutarate-dependent ten eleven translocation (TET) enzymes and lysine demethylases. Both classes of enzyme control removal of methyl groups from chromatin 46 : TETs hydroxylate 5-methylcytosine in CpG dinucleotides in DNA (a step towards DNA demethylation), whereas lysine demethylases target histones, leading to their demethylation 46 . Thereby, cancer cells that have high abundances of these metabolites are characterized by histone and DNA hypermethylation, illuminating the link from oncometabolites to the epigenome.
In addition to enzyme inhibition, other distinct biological activities for individual oncometabolites have been described. Fumarate can react with the thiol groups of cysteine residues. One example target of this reaction is protein KEAP1, which is an adaptor for the Cullin3-based ubiquitin E3 ligase complex, which rapidly ubiquitylates the transcription factor NRF2 and leads to its degradation. This reaction results in acylation (succinylation) of a cysteine residue and therefore inhibition of KEAP1 activity 47 . Consequently, NRF2 is activated, driving antioxidant and anti-inflammatory gene expression ( fig. 2b ). This mechanism has been shown to be responsible for the increased cyst size in renal cancer 47 . Fumarate also mediates succination (a chemical modification of cysteine yielding S-(2-succinyl)cysteine) of other proteins involved in redox metabolism, which is generally potently activated in cancer cells as a means of counteracting increased levels of reactive oxygen and nitrogen species generated as a consequence of metabolic rewiring 48 . Fumarate has also been suggested to modify other metabolites, such as glutathione 49 , thereby increasing oxidative stress and senescence. Recently, d-2-hydroxyglutarate has also been shown to inhibit the activity of branched chain amino acid transaminase 1 (BCAT1) and BCAT2, two α-ketoglutarate-dependent enzymes, which are involved in the biosynthesis of amino acids leucine, isoleucine and valine 50 . It should be noted that a number of additional metabolites have been classified as oncometabolites, including glycine, glucose and lactate, and most of these metabolites are related to aerobic glycolysis, glutaminolysis or one-carbon metabolism 51, 52 .
Metabolome-driven omics alterations
The examples discussed above encompass rather reductionist approaches to study the bioactivity of metabolites, focusing on single metabolites and reactions. However, there is now evidence that the metabolome has a largescale, systemic impact on other omes. Foundational studies used dietary restriction in mouse models to limit nutrient availability and alter metabolism and found a dramatic change in gene expression alongside amelioration of phenotypes associated with ageing 53 . It has also emerged in the past decade that control of the epigenome is determined by metabolic status 54 . However, only a few studies have analysed the impact of metabolic changes or metabolite supplementation on the other omics layers in a systematic manner. In one study, large-scale integration between metabolomics and transcriptomics levels was investigated during macrophage polarization, revealing metabolic features associated with alternatively activated macrophage states 55, 56 . Furthermore, systemic metabolite-protein interactions have been successfully surveyed in bacteria, which provided evidence for the role of the metabolome in proteome-wide complex formation (the protein interactome). In this case, ATP was shown to promote the formation of complexes of a bacterial UTP-glucose-1-phosphate uridylyltransferase, galF 55, 56 ( fig. 3d) . The protein-metabolite interaction landscape has also been probed by protein-centric approaches (protein arrays) in yeast, revealing largely unexplored regulatory connections, including alteration of YPK, a mammalian AKT analogue, by the yeast cholesterol equivalent, ergosterol 57 . As a final example, one recent study analysed the transcriptome, proteome and metabolome of various yeast strains that were deficient in histidine, leucine, methionine and uracil biosynthesis 58 . Integrated analyses revealed that gene expression and protein expression are largely controlled by the ability to perform biosynthesis of these metabolites, despite metabolite supplementation in the medium, suggesting a systems-wide modulation of various omics levels by the metabolic background.
Altogether, the active metabolome empowers and mediates basic biological processes such as signal transduction, proteostasis and regulation of gene expression on a systemic level. This multitude of metabolite-induced and metabolite-endowed omics modulations is a current focus of several investigations. However, methods to study the metabolome, in particular, the active metabolome, on a global scale and approaches to interrogate the interplay between the metabolome and the other omes have been developed only very recently. Multiomics approaches currently focus on meta bolomeproteome crosstalk and face several challenges (see Multi-omics integration for activity screening below). Further technological improvements are necessary to unravel the complexity of metabolite-induced macromolecule activity to ultimately control the pheno type. In any case, the current literature already shows that identified metabolites from metabolomic studies can modulate physiology, a concept that revolutionizes conventional omics technology thinking: meta bolites are not providing a simple readout for the other omics layers but can act as master regulators of the biological system 14 . discovering bioactive metabolites Identification of phenotype-modulating metabolites is a complex process. First, metabolites with differing abundance in different conditions are identified, which provides an initial correlation of the metabolome with the phenotype. At this stage, identified metabolites can be assigned to the known metabolic pathways using bioinformatics-based analyses. Once lists of candidates are established (including the affected metabolites themselves and potentially also metabolites implicated in the common pathways), their fate can be tracked using isotope-based tracing through the metabolome (flux analysis), which enables determination of the time-dependent activity of the respective enzymes and
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A high-throughput method used to determine the interactions of proteins (for example, with candidate metabolites).
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A mass-spectrometry-based technique that is used to examine production and consumption rates of metabolites by tracking isotopes.
thus the activity of biochemical pathways 59, 60 . Finally, metabolomics-guided activity screening of the identified compounds can be performed using in vivo and in vitro phenotype, omics and chemical biology strategies. On the basis of the known physico-chemical properties of metabolites, it is also possible to predict metabolite bioactivity using advanced in silico approaches, which nowadays are largely available for many metabolites. Metabolomics data can also be cross-correlated with other omics data. This multi-omics analysis provides a mechanistic understanding of the biological role of metabolites. It can also improve the assignment of target metabolites within metabolic networks and eventually can assist in candidate metabolite selection for further screening. Together, these approaches establish a bioactive metabolite discovery framework, which we refer to as activity metabolomics.
Metabolite identification, quantification and selec tion. Historically, metabolite detection, identification and quantification have been accomplished using biochemical approaches, such as labelling including radiolabelling, fractionation and in vitro testing. Now, metabolomics offers a unique framework for discovery Metabolomics-guided identification of bioactive metabolite candidates starts with a comparative metabolome analyses -a discovery-oriented untargeted or broad-scale targeted profiling analysis is followed by data mining to select the metabolite candidates on the basis of significance (P value), amplitude (fold change) and direction of its change (that is, accumulation or depletion) between experimental conditions (for example, perturbation and control) in the studied system (for example, cell media, mice or human plasma). To this end, statistical approaches are applied, and the candidate metabolites with potential influence on the phenotypic change are identified using spectral libraries. Further bioinformatics-based analyses with the use of metabolic pathway databases can be applied to assign the candidate metabolites to a locally enriched part of the metabolic network (a distinct module or biochemical pathway). Protein and gene expression data (as a result of proteome and/or transcriptome analyses) can be further used to support and help in pathway annotation (for example, the depletion of one metabolite will usually be coupled to the significantly higher expression of the enzyme or enzymes responsible for its consumption). To gain further insight into the metabolic fate of the candidate metabolites, the next step involves stable isotope-assisted ( 13 C or 15 N) tracing experiments to identify the active pathways used for metabolite catabolism. Different conditions can be tested in a longitudinal assay to gather information about metabolite uptake and conversion (by measuring label-enriched metabolites based on mass-spectrometry-derived isotopologue abundance analyses or by performing NMR-based flux analysis). Lastly , metabolites are tested for bioactivity using in vitro cell or organoid models or in vivo models. These assays provide direct information about how the phenotype is affected or modified via endogenous metabolite supplementation (ingestion through diet, drinking water or by addition to the cell culture medium). Metabolite bioactivity can also be surveyed by chemical biology approaches and/or can be predicted with the use of advanced in silico models.
www.nature.com/nrm that can, and has been, applied at multiple levels (fig. 4) . The identification process is one of the most important aspects in the discovery of bioactive metabolites. Mass-spectrometry-based metabolomics data acquisition and annotation are primarily defined by identifying metabolite features with a specific mass-to-charge ratio (m/z). This annotation of chromatographic peaks is a multicomponent and challenging aspect of data processing and has been extensively reviewed 61 . . The challenges in data analysis and sharing, especially for nonspecialized laboratories, were recently addressed by the development of technologies and databases based on cloud-based computing (Box 1). Once metabolites are identified, their abundance is quantified on the basis of the signal intensity or peak abundance. A metabolome-based strategy for identifying candidates with biological activity would then be combined with statistical analysis of metabolomics data sets to uncover significant differences between them (to detect differently regulated metabolites, for example, between an experimental sample and control) 76 . Bioinformatics-driven metabolic pathway and network analysis can be further used to reduce the com plexity of the data. This feature has been recently incorporated into XCMS Online 77 and is also available via MetExplore 78 and other platforms [79] [80] [81] . The aim of these approaches is to prioritize the metabolites involved in distinct modules of the metabolic network or locally enriched parts of the metabolic network, thus reflecting the true activity (while assuming that the false matches will be distributed randomly across the network). Altogether, these approaches gene rate a list of metabolites that can be linked to a certain phenotypic change and that can next be screened for their bioactivity.
Metabolic activity screening strategies. Identifying bioactive metabolites from the candidate list can be achieved through multiple strategies. There are a host of examples in which metabolomics in combination with orthogonal molecular biology and computational approaches has been successfully used to identify bioactive metabolites 14 . In each of these examples, the primary step in determining activity has been the use of an appropriate screening strategy. This includes screenings for gene expression, protein expression and protein activity (for example, enzyme activity), modulation of desired cellular phenotypes and performance of in vivo phenotypic studies directly on an organism. TABle 1 lists the principles behind these assays. In vivo studies can provide direct phenotypic evaluation of the role of a meta bolite. However, they are low throughput. Cell-based assays can provide high throughput and enable the analysis of cell morphology, biophysical cell function and chemical and physiological properties and can leverage a variety of molecular biology tools such as fluorescent or luminescent reporters. For the fields of metabolite-epigenome and metabolite-genome interactions, these tools mainly comprise nucleotide sequencing approaches such as chromatin immunoprecipitation followed by sequencing (ChIP-seq) and detection of methylated DNA using bisulfite sequencing. More recently, the field of chemical proteomics has emerged to study metabolite-protein and small-molecule-protein interactions in vitro. This can be accomplished, for instance, via protein arrays that interrogate chemical binding of distinct metabolites to various proteins 82, 83 or, more recently, via thermal proteome profiling, a method that relies on the principle that the temperature for thermal degradation of proteins (melting point) is
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Box 1 | Cloud-based computing and metabolomic databases
metabolomics, a multidisciplinary technology that is now evolving at an increasingly rapid pace, nonetheless may still be regarded as an emerging discipline. Its initially slow progression stems from the intensive resource commitment a truly comprehensive metabolomics laboratory requires, including high-sensitivity triple quadrupole mass spectrometer systems, NmR technologies and high-resolution mass spectrometry systems for untargeted metabolomics analyses. This commitment limits metabolomics accessibility to biologists owing to the required expertise, instrumentation and, most importantly, bioinformatics support. In addition, although data generation occurs mainly through collaborations or fee-for-service facilities, the challenge to identify the most meaningful bioactive metabolites and interpret their function within a biochemical context remains. To address this challenge, cloud-based bioinformatics platforms represent a novel paradigm of how resources can be made available on a global scale and large amounts of data can be translated into biological insights.
The greatest value of the universal-access options provided by the cloud is the fast and simple sharing of resources. Among many other algorithms (see Metabolite identification, quantification and selection), XCmS was originally developed as a metabolomics data-processing algorithm to extract metabolite features out of raw mass spectrometry data and to perform statistical analysis 62 . Today, it is available as a cloud-based online resource with over 27,000 users, allowing them to upload mass spectrometry data files and share the processed results with an individual collaborator and/or make them publicly available. This type of cloud-based platform increases the field's ability to compare results with those available from public repositories and to perform metabolomics meta-analyses. Because of the conserved nature of metabolites across evolution, these analyses are transposable over a variety of phyla and species, ranging from bacteria to plants to higher organisms 140 . Cloud-based computing has also addressed the issue of metabolite identification with the multiple databases available, specifically databases that contain tandem mass spectrometry data from defined compounds. In addition to XCmS, other cloud-based approaches in metabolomics exist 141 or are emerging 142 , and public online databases such as metabolights 105 and metabolomics Workbench 106 enable the first cloud-based analyses that will further improve in the future. Altogether, cloud-based computing is an important tool in modern metabolomics that readily offers the ability to integrate the rich sources of archived data from the multiple repositories available 79 , which remains one of the key challenges of systems biology.
Despite many advantages, cloud-based computing faces some challenges that need to be considered. The user of the cloud needs an efficient web connection for data uploading and processing and may have limited flexibility and control over the resources. The provider of the cloud requires server resources that expand according to the ever-growing amount of data and high-level security. However, even with these challenges, it appears that biology and cloud-based computing have already become irrevocably intertwined. This is particularly true for omics disciplines, which deal with data sets reaching the terabyte range and are driven by the increasing performance of high-throughput methods, such as next-generation sequencing or high-resolution mass-spectrometry-based metabolomics and proteomics.
shifted upon small-molecule binding. Thermal proteome profiling involves a thermal shift to denature proteins within living cells or a cell extract in the presence of different metabolites 84 . Many other chemical proteomics approaches exist 85 that are either metabolite or protein centred, including protein stability assessed from rates of oxidation (SPROX) 86 or limited proteolysis 87 . Beyond in vivo and in vitro screening technologies, advanced, computer-based prediction approaches are being adopted to evaluate metabolite bioactivity. One recent development is the use of neural networks that can be trained by large data sets of the activity, physicochemical properties and structural information of small molecules, which are available in the ChEMBL database 88 . Using this information to train a neural network might result in an algorithm capable of predicting the possible bioactivity of hundreds, if not thousands, of metabolites evolving from exploratory metabolomics. In turn, metabolomics data might be superimposed on activity constraints such as physico-chemical properties, or distinct functional groups, resulting from a neural network, thereby limiting the actual chemical space, which ultimately has to undergo in vitro and/or in vivo bioactivity testing. Another interesting source of knowledge for limiting the candidate list for activity screens stems from drug metabolism, in which distinct molecular sites prone to metabolic activation can be predicted by specialized and highly evolved in silico approaches 89 . Metabolomics can also benefit from cognitive computing approaches. These are currently under development, but one recent example includes the use of natural language processing of the literature abstracts available in Medline to identify new harmful molecules, such as toxicants, aiding in the functional interpretation of their roles 90 . In addition to the use of advanced in silico approaches, closing mass balances of metabolic models might also be an interesting approach to simplify activity screening. Closing mass balance involves mathematical operations that ensure that the input and the output of a system are in line with the law of mass action (meaning that the rate of chemical reactions is proportional to the product of the concentrations of the reactants). As recently shown, closing the mass balance in metabolic models of Bordetella pertussis enabled the authors to gain deeper insight into the biology of the bacterium by curating and completing their metabolic model. The metabolic model of B. pertussis showed a substantial nitrogen imbalance, leaving approximately 30% of nitrogen from the source glutamate unaccounted for. Using liquid-chromatography-mass-spectrometry analysis, 11 novel nitrogen-containing metabolic end products could be identified. On the basis of the nature of these metabolites, the authors suggested physiological roles for these alternative nitrogen sinks beyond mere nitrogen excretion. Next, the authors used their curated metabolic model to compute the minimal nutrient inputs supporting the growth of B. pertussis in order to rationally design novel growth media. Most interestingly, their model predicted thiosulfate as a possible sulfur source, including novel metabolic pathways for its conversion. Together with the identified nitrogen sinks, the presented approach shed light on possible host-microorganism interactions, as well as the metabolic flexibility of B. pertussis, and enabled rationally designed novel growth media, increasing pertussis toxin production for the generation of vaccines against whooping cough 11 . It is worth noting that some screens can be time intensive and costly and are largely limited to specialized laboratories. In order to effectively preselect potential candidates following metabolomics data processing (thereby accelerating the general assays delineated in It is also possible to imagine that comprehensive and diverse libraries of metabolites could be used for high-throughput testing of bioactivity. For example, METLIN currently has more than 300,000 individual small molecules, including metabolites and small peptides. This approach using robotic acoustic dispensing devices coupled with multiple known biological screens is already widely used in pharmaceutical and biotechnology industries and could provide a brute-force approach to metabolite activity screening.
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A chemical law defining that a reversible chemical reaction in equilibrium is directly proportional to the product of the concentrations of the reactants. ; identification of bioactive drug metabolites 146, 147 Affinity Prioritization of bioactive natural products using massive multi-informational molecular networks Molecular networks embedding known bioactivity and taxonomical data to highlight potentially bioactive scaffolds in crude extracts
Computational approach that facilitates the identification of potentially bioactive compounds using databases and molecular or fragmentation similarity in mass spectra
Complete structural elucidation of active compounds remains a challenge Isolation of new cytotoxic prenylated stilbenes of the schweinfurthin series from Macaranga tanarius 156, 157 CSB, Cockayne syndrome protein B; GAM, genes and metabolites; HPLC, high-performance liquid chromatography; STING, stimulator of interferon genes.
NaTuRe RevIeWS | MoLECuLAr CELL BioLoGy
Multi omics integration for determining activity. Beyond pure metabolomics, multi-omics data correlation and integration can provide an additional layer of information to improve the metabolite selection process 91 . For example, metabolite candidates may be integrated with transcriptomics and proteomics data as a follow-up to pathway analysis by deducing their overlap in the selected pathways of interest. A variety of integrated data sets consisting of proteome, transcriptome and metabolome data have been generated in different research areas, ranging from cancer metabolism 92, 93 and plant physiology 94 to microbiology 94, 95 . The aim of the multi-omics integration is to enable the determination of the activity of distinct metabolites through quantitative modelling, thereby allowing a targeted intervention on a specific pathway. To this end, it is very important to reduce the complexity of a vast amount of data. This can be done by multiple mathematical approaches, for instance, by adding meta bolite and other omics data to curated pathways or by modelling novel pathways and fluxes by the data. It has to be stated that the area of multi-omics integration is an ongoing effort and that multiple approaches are currently being pursued 96, 97 . In most of the studies, multi-omics integration is based on gene nomenclature linked to unique metabolite identifiers and involves combining previously generated pathway information, which is available in pathway databases such as KEGG, Reactome, the small molecule pathway database (SMPDB) 98 and Biocyc; platforms such as Recon and ChemRICH; or is generated by metabolite set enrichment (available via the MetaboAnalyst platform) [99] [100] [101] [102] [103] [104] . The advantage of using this pathway information is the ability to reduce complexity and to filter noise. The recently introduced metabolomics-guided systems biology approach integrates multi-omics data, where all other omics data layers (on gene and protein expression) are mapped onto the untargeted metabolomics-derived pathway activity information 77 . Several other approaches for multi-omics pathway integration exist 93 and network-based and machine learning approaches are emerging.
Integrating the metabolome and other omics layers can be a challenging pursuit. In fact, many researchers acquire complex data sets without a preset integration strategy. Robustness of data acquisition, artefacts introduced by a sample harvest (batch effects) and the distinct features of the different omics data sets must be adequately considered. The challenges in multiomics data integration are reviewed elsewhere 96, 97 , but the most important ones consist of noise removal, data prefiltering, matching of various identifiers of molecules, selection of data dimensionality reduction methods and finally selection of computational approaches and mathematical models to apply to the acquired omics data, followed by model validation and the further integration into trans-omics network modules. The ability to streamline and efficiently advance these approaches is currently under development. Challenges also include the reality that metabolic networks cannot be sufficiently validated owing to technology limitations (for example, limited metabolite coverage as a consequence of analytical bias). Finally, as pointed out, the entirety of omics data is often not utilized in an adequate and comprehensive way 96 . One limitation on the metabolomics side is the lack of appropriate archives and data-sharing strategies; these concerns, however, are gaining more and more attention, as exemplified by the foundation of public, cloud-based repositories of metabolomics data such as MetaboLights 105 and Metabolomics Workbench 106 . Importantly, according to a large number of high-visibility reports in the current literature, it is common that a reductionist experiment is conducted as a conclusive experiment that potentially increases the impact of the study. However, this commonly used procedure does not take advantage of the data set as a whole, and consequently, the majority of multi-omics data are not being used and are not made publicly available 96, 107 . However, once acquired and integrated, the multilayered omics strategies can be useful, especially if applied to in vivo metabolic analyses.
It is anticipated that genome-scale modelling of metabolic processes, big data analyses and machine learning strategies [108] [109] [110] will be integrated to further predict metabolic alteration in a given biological system. In fact, the power of this integrative omics approach has already been shown by in vivo and in vitro modelling studies that reconciled multilayered omics data acquisitions and metabolic and other phenotypes over a large number of experiments (performed in different conditions) and were able to accurately predict biological behaviour. For example, in a recent machine learning approach, proteomics data were used to predict the yeast meta bolome in kinase-knockout strains, covering the entire yeast kinome 111 . Another example is a platform that was shown to accurately predict genome-scale expression and concentration of genes, proteins and metabolites, metabolic fluxes and growth rates of Escherichia coli in different conditions (which included variables such as medium composition, bacterial strain, genetic perturbations and stress factors) 112 . While the current goal of these integrated, multiomics approaches is the generation of accurate biological models that can predict how the system behaves in a given condition, the metabolomics-guided multiomics perspective is different: our ultimate goal is to use multi-omics integration to identify the best candidates for activity screening. For example, mapping downstream metabolic changes onto metabolic pathways and biological networks can provide mechanistic insights, especially when associated with other omics data. Within these platforms, automated, predictive pathway analysis enables straightforward and efficient metabolite mapping to background-knowledge databases that can be either curated reference pathway databases or genome-scale networks. However, the available metabolic spectral databases cover only a fraction (up to 60%) of the genome-scale metabolism, suggesting a general, yet addressable, limitation of the metabolomics-guided strategy 113 . Therefore, the analysis of the multidimensional and integrated omics landscape yields unanticipated opportunities and out-of-the-box solutions for predicting metabolites that modulate phenotype and
Metabolite set enrichment
A method of identifying patterns of regulated metabolites using predefined metabolite lists. it is an analogue of gene set enrichment.
Untargeted metabolomics
A global method that attempts to measure all or as many molecules as possible in a sample. By contrast, targeted metabolomics is a method in which a specified, predefined entity of molecules is measured. Both methods can be based on mass spectrometry or NMr. 
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Fig. 5 | Metabolite activity for phenotype modulation. A | Metabolomics has already made a considerable impact in a wide variety of scientific areas through discovery of active, mainly endogenous metabolites that can regulate different biological processes and thus modulate the phenotype in health and disease. Metabolites can also be used in biotechnology to improve biosynthetic production. B | Metabolic activity of α-ketoglutarate is context-dependent. α-Ketoglutarate is an endogenous metabolite (that can be induced, for example, by exercise) but can also be supplemented. Direct supplementation has a wide effect on various systems via different mechanisms. Ba | In bacteria, intracellular α-ketoglutarate is induced by nitrogen limitation and inhibits enzyme I (the first enzyme of the phosphoenolpyruvate:sugar phosphotransferase system in bacteria, which regulates metabolism in response to the availability of carbohydrates) to decrease glycolytic flux and to couple nitrogen consumption to glucose consumption. Bb | In Caenorhabditis elegans, α-ketoglutarate addition leads to the inhibition of the ATPase β subunit, resulting in inhibition of ATP production, oxygen consumption and TOR signalling, thereby promoting autophagy. These mechanisms all result in the extended lifespan of the worm. Bc | In embryonic stem cells, an increased α-ketoglutarate-tosuccinate ratio drives activation of Jumonji C (JMJC)-domain-containing histone demethylases (such as JMJD3) and the ten eleven translocation (TET) family of DNA demethylases (TET1 and TET2) to drive epigenetic changes. These changes include reduced trimethylation at H3K27me3 and also reduced methylation of DNA (5-methylcytosine reduced). This type of change enables the increased gene expression required for pluripotency. Bd | In T cells, α-ketoglutarate promotes mTOR signalling and induces the T cell-specific transcription factor T-BET via an unknown mechanism to promote differentiation of naive T cells to T helper 1 (T H 1) cells over regulatory T cells. Be | In specialized mammalian organs, such as the kidney , α-ketoglutarate can be secreted to control organ function in a paracellular manner. Urinary α-ketoglutarate released in response to metabolic stress results in activation of the OXGR1 receptor and subsequent activation of salt transporters to regulate electrolyte balance and, presumably , hypertension.
thus has the potential to drive the development of activity metabolomics.
applications of activity metabolomics Bioactive metabolites are highly abundant and known to alter phenotypes in a variety of organisms ranging from relatively simple prokaryotes to human cells. Accordingly, the applications for bioactive metabolites are vast (fig. 5A ). For instance, metabolites can be used to support biotechnological production, as exemplified by B. pertussis toxin production or E. coli protein production 11, 12, 114 . The mammalian microbiome is also susceptible to modulation by small molecules and has been shown to be modulated by the host's metabolome 115 , or in reverse, microbiome-derived metabolites, such as butyrate, can be used to impact a host's physiology, including immune cells 116 and satiety 117 . In the emerging field of immunometabolism, it has been demonstrated that prostaglandin E2 regulates immune responses: on the basis of its spatial and temporal concentrations, it has emerged as a key mediator for lipid class switching and inflammation resolution 118 . Thus, modulation of synthesis, degradation and/or cellular responsiveness to prostaglandin E2 could be used as a therapeutic approach to drive specific immune responses [119] [120] [121] . On an organ level, metabolites were shown to control pathophysio logical reactions, such as asthma via leukotrienes 122 . In complex organisms, nutritional interventions such as supplementation of omega-3 fatty acids were shown to have multiple benefits. This is illustrated by the improved condition of patients with rheumatoid arthritis 123 or the significant reduction in cardiovascular events in patients with hypertriglyceridaemia when given omega-3 fatty acids in a high dose as an ethyl ester (ethyl eicosapentaenoic acid; also known as icosapent ethyl) 124 without severe side effects 125, 126 . In addition, a plethora of studies have analysed the phenotypic changes associated with feeding various supplemented diets to model organisms and their impact on ageing [127] [128] [129] . Apart from dietary supplementation, bioactive metabolites are used in the fields of pharmacology and toxicology to reduce compound toxicity (for example, to reduce methanol poisoning by administration of ethanol or to scavenge toxic metabolites, for example, sodium 2-mercaptoethanesulfonate for certain chemotherapeutics or acetylcysteine in the case of paracetamol (acetaminophen) poisoning) and to take advantages of drug synergies with endogenous metabolite classes for improved treatment outcomes 130 . Even very simple and inexpensive meta bolites, such as glutamine, can be utilized to treat complex diseases such as sickle cell anaemia, as was recently investigated in a phase III clinical trial 131, 132 . These examples show the wide applicability of using bioactive metabolites to modulate biological processes, to induce shifts in cellular metabolic states (for example, to drive cell activation, differentiation or proliferation) and to drive complex tissue functions.
Notably, the effect of a metabolite is determined by the context, and the phenotype associated with it can vary largely with the biological system to which it is applied. A prominent example of a bioactive metabolite that alters phenotype in a context-dependent manner is α-ketoglutarate ( fig. 5B ): in bacteria, it regulates glucose metabolism and uptake 133 ; in Caenorhabditis elegans, α-ketoglutarate extends the lifespan by negatively modulating mitochondrial respiration, ATP production and, in effect, autophagy 134 ; in embryonic stem cells, α-ketoglutarate modulates pluripotency by promoting the activity of jumonji C (JMJC)-domain-containing histone demethylases and the TET family of DNA demethylases, thereby regulating the histone methylation and DNA methylation landscapes 135 ; in immune cells, it supports differentiation of naive T cells towards T helper 1 (T H 1) cells by modulating mTOR signalling and promoting the expression of T H 1-cell-associated transcription factor T-BET and thereby regulates the balance between T H 1 and regulatory T cells 136 ; and α-ketoglutarate also binds to the GPCR OXGR1 (localized chiefly in the kidney), promoting increased synthesis of salt transporters to drive salt reabsorption and to regulate salt balance and blood pressure 137, 138 . In humans, α-ketoglutarate was reported to promote wound healing via a multitude of processes involving ERK kinases 139 . The goal of activity metabolomics is to provide the framework for unravelling such context dependencies. Thus, the current challenge of activity metabolomics is to link the metabolome with an organism's phenotypic states in a systematic and quantitative fashion. This goal will require the generation of comprehensive metabolomics and phenotypic data sets as well as robust methods to computationally integrate multi-omics data.
conclusions The concept that metabolites can act as controllers of the phenotype -as opposed to being simply biomarkers of phenotypic states -is gaining new attention as metabolomics becomes more mainstream. The term activity metabolomics is introduced here to describe how meta bolomics technologies can be employed to identify bioactive metabolites and to emphasize that metabolomics as a technology has soared above a purely biomarker-driven approach. The challenge that this approach of activity screening guided by metabolomics is facing is the need for increased robustness, which can be achieved by computationally combining meta bolomics, systems biology and bioactivity data, enabling us to identify metabolites with the highest potential to modulate biological processes and cell physiology. In addition, although it is easy to get lost in the details of the problems (for example, metabolite identification and metabolite annotation), many of these issues have been or are on the way to being resolved. The ultimate goal of these technological achievements is to use activity metabolomics as the main tool for systematic bioactive metabolite discovery rather than using largely focused (that is, chemical proteomics) or cumbersome (that is, fractionation) approaches. Once this is accomplished -by enabling the identification of active molecules that modulate the phenotype of the system of interest -activity metabolomics has the potential to impact multiple scientific disciplines.
Published online 27 February 2019
www.nature.com/nrm
